Skip to content

Effectiveness Homoeopathic Medicines for Pre-diabetes

Study to Compare Effectiveness of Potencies Within and Beyond Avogadro Limit of Individualised Homoeopathic Medicine among Pre-Diabetic Adults by Assessing Glycemic Control: An Open-Level Randomized Parallel-Arm Trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/063065
Enrollment
70
Registered
2024-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R739- Hyperglycemia, unspecified

Interventions

Intervention1: Individualized homoeopathic medicines with potencies within Avogadro limit (potencies within 24X in decimal scale and 12CH in centesimal scale): Arm-1: Intervention is planned as admini
repetition depending upon the individual requirement of the cases. All medicines will be procured from a Good Manufacturing Practice (GMP)-certified company. Duration of this therapy: 3 months Contro
repetition depending upon the individual requirement of the cases. All medicines will be procured from a Good Manufacturing Practice (GMP)-certified company. Duration of this therapy: 3 months

Sponsors

Metropolitan Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient age within 20-79years, both male and female. 2. Indian Diabetic Risk Score (IDRS) above/equal to 60. 3. Impaired glucose regulation i.e. fasting plasma glucose concentration value 100-125mg/dL and/or two hrs. post 75gm glucose load plasma glucose value 140-199mg/dL. 4. Patients with written consent to participate in this study. 5. Literate patients.

Exclusion criteria

Exclusion criteria: 1. Patient suffering from uncontrolled systemic illness, life-threatening infections or any vital organ failure/s 2. Patient already undergoing homoeopathic treatment for any chronic disease 3. Patient with self-reported immune-compromised states 4. Pregnant women/lactating mother 5. Patient without consent to take part or Illiterate patient

Design outcomes

Primary

MeasureTime frame
Glycosylated hemoglobin (HbA1C)Timepoint: Baseline, after 3 months

Secondary

MeasureTime frame
Blood glucose level after 2 hours of 75 gm glucose loadTimepoint: Baseline, after 3 months;Fasting blood glucose levelTimepoint: Baseline, after 3 months

Countries

India

Contacts

Public ContactAvidipta Hazra

Metropolitan Homoeopathic Medical College and Hospital

drdebarsi@gmail.com8240821020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026